Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	112788
Country	India

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Sayan Malakar, Suprabhat Giri, Anuraag Jena and Preetam Nath
Funding Agency and Grant Number
Corresponding Author	Suprabhat Giri, Associate Professor, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Kushabhadra Campus, 5, KIIT Road, Patia, Bhubaneswar 751024, Odisha, India. supg19167@gmail.com
Key Words	Janus kinase inhibitors; Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease
Core Tip	Janus Kinase inhibitors are reserved for moderate-to-severe inflammatory bowel disease (IBD) after biologic failure or steroid dependence. Carefully selecting patients based on their cardiovascular, thromboembolic, and infection-related risks is of paramount importance. Tofacitinib is an excellent choice for patients with moderate to severe ulcerative colitis (UC) and acute severe UC.  Upadacitinib is currently approved for both refractory UC and Crohn’s disease (CD); however, emerging data suggest its beneficial role in acute severe UC. Limited evidence exists for the combination of small molecules and other biologicals in patients with difficult-to-treat IBD and peri-anal CD. Close monitoring of side effects is advocated in such patients. More data is warranted on their role in extraintestinal manifestations, IBD in pediatric and pregnant patients with IBD.
Citation	Malakar S, Giri S, Jena A, Nath P. Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2025; In press

Received	2025-08-07 01:48
Peer-Review Started	2025-08-07 01:49
To Make the First Decision
Return for Revision	2025-08-20 07:57
Revised	2025-09-01 17:58
Second Decision	2025-11-24 02:49
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-11-24 10:17
Articles in Press	2025-11-24 10:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com